YTRACIS

This brand name is authorized in Austria, Estonia, France, Israel, Lithuania, Poland, Singapore, Spain, UK.

Active ingredients

The drug YTRACIS contains one active pharmaceutical ingredient (API):

1	Yttrium ⁹⁰Y chloride UNII TN98A27Q17 - YTTRIUM CHLORIDE Y-90
	Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr). It decays by emission of beta radiation of 2.281 MeV (99.98 %) of maximal energy to stable zirconium (90Zr). 90Y-yttrium has a half-life of 2.67 days (64.1 hours).
	Read more about Yttrium ⁹⁰Y chloride

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
YTRACIS Radiopharmaceutical precursor, solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V07AY	Other non-therapeutic auxiliary products	V Various → V07 All other non-therapeutic products → V07A All other non-therapeutic products
Discover more medicines within V07AY

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1208214
ES	Centro de información online de medicamentos de la AEMPS	03250001
FR	Base de données publique des médicaments	65491383
GB	Medicines & Healthcare Products Regulatory Agency	398576
IL	מִשְׂרַד הַבְּרִיאוּת	6748
LT	Valstybinė vaistų kontrolės tarnyba	1029595
PL	Rejestru Produktów Leczniczych	100126560
SG	Health Sciences Authority	13305P